AHA summary of Pfizer COVID-19 vaccine EUA
Following the Food and Drug Administration’s Dec. 11 emergency use authorization of Pfizer, Inc.’s BNT162b2 mRNA COVID-19 vaccine, AHA released a Special Bulletin with important details for hospitals and health systems.
The summary covers dosing, storage and handling, preparation, and contraindications and adverse reactions. View the AHA Special Bulletin and review AHA resources on this and other COVID-19 vaccines and treatments.
Also over the weekend, the Centers for Disease Control and Prevention formally recommended the vaccine’s use for patients age 16 and older
Related News Articles
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Medicare & Medicaid Services Oct. 22 released final guidance detailing reporting requirements for the hospital respiratory data condition…